Simulations Plus

Investment to accelerate innovations in biopharma development through Corporate Development Initiative

Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06

Updates fiscal 2025 revenue guidance range

Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET

Updates fiscal 2025 revenue guidance range

Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET

Newest version of the quantitative systems toxicology (QST) software supports drug-induced liver injury (DILI) prediction for pediatric patient populations

Modeling and simulation will be a key component for shift to non-animal methodologies

Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy combined with built-in coaching and training

Total revenue grew 23% year-over-year driven by strong growth in both software and services

Simulations Plus will be participating in a fireside chat at the KeyBanc Capital Markets Virtual Healthcare Investor.

Industry partners to provide funding and data to support ACAT™ model improvements

SLP’s technology and expertise accelerates drug development and supports critical advancements in global healthcare

Total revenue up 31% year-over-year primarily driven by strong software growth

Funded collaboration will leverage current FDA partnership to include additional LAI technologies

Simulations Plus to Participate in the Stephens Annual Investment Conference

Collaboration goal to develop alternative methods to assess clinical performance of product variants under different conditions

Partnership will advance the field of ligand-based virtual screening to improve drug design and optimization activities

Updated quantitative systems toxicology (QST) software investigates and predicts drug-induced liver injury (DILI)

Enhancements in key models power HT-PBPK simulations and AI-driven drug design with unprecedented performance and accuracy.

Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Leadership Forum

Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals.

Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15

Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance